Table 1 Demographic and clinical data of study participants
| Â | ICAS | WICAS | P value |
|---|---|---|---|
(n = 361) | (n = 598) | ||
Men/female, n | 125:236 | 228:370 | 0.561†|
Age (years ± SD) | 72.3 ± 4.2 | 71.9 ± 3.9 | 0.204* |
Diabetes duration, (years ± SD) | 13.1 ± 4.2 | 12.4 ± 3.5 | 0.247* |
BMI (Kg/m2 ± SD) | 30.2 ± 6.5 | 27.6 ± 4.8 | <0.01* |
Smoking (current), n (%) | 125 (34.6) | 194 (32.4) | 0.145†|
Smoking (former), n (%) | 163 (45.2) | 279 (46.7) | 0.112†|
Hypertension, n (%) | 234 (64.8) | 248 (41.5) | <0.01†|
CAD, n (%) | 201 (55.7) | 191 (31.9) | <0.01†|
HIS, n (%) | 174 (48.2) | 0 (0.0) | <0.01†|
PAD, n (%) | 115 (31.9) | 106 (17.7) | <0.01†|
Hypercholesterolemia, n (%) | 291 (80.6) | 161 (26.9) | <0.01†|
LDL-C (mg/dL ± SD) | 213 ± 29.8 | 149 ± 21.2 | <0.01†|
Triglycerides (mg/dL ± SD) | 184 ± 21.3 | 143 ± 18.8 | <0.01†|
Statins, n (%) | 295 (81.7) | 165 (27.6 %) | <0.01†|
Antihypertensive drugs, n (%) | 229 (63.4) | 237 (39.6) | <0.01†|
Anti-diabetic treatment | |||
 Diet only, n (%) | 38 (10.5) | 65 (10.9) | 0.563†|
 Oral Agents, n (%) | 178 (49.3) | 292 (48.8) | 0.428†|
 Insulin therapy, n (%) | 145 (40.2) | 241 (40.3) | 0.394†|
eGFR (mL/min/1.73 m2 ± SD) | 68.8 ± 15.2 | 91.1 ± 19.8 | <0.001 |
Phosphate (mg/dL ± SD) | 3.01 ± 1.32 | 2.89 ± 1.13 | 0.234 |
Calcium, mg/dL | 9.3 ± 0.4 | 9.5 ± 0.6 | 0.763 |